CN112022933B - 一种治疗气滞血瘀型胃痛的药物组合物 - Google Patents
一种治疗气滞血瘀型胃痛的药物组合物 Download PDFInfo
- Publication number
- CN112022933B CN112022933B CN202011094000.4A CN202011094000A CN112022933B CN 112022933 B CN112022933 B CN 112022933B CN 202011094000 A CN202011094000 A CN 202011094000A CN 112022933 B CN112022933 B CN 112022933B
- Authority
- CN
- China
- Prior art keywords
- fluid extract
- mixing
- weight
- hours
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 210000004369 blood Anatomy 0.000 title claims abstract description 37
- 206010000087 Abdominal pain upper Diseases 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 208000011580 syndromic disease Diseases 0.000 title description 10
- 239000003814 drug Substances 0.000 claims abstract description 61
- 229940079593 drug Drugs 0.000 claims abstract description 42
- 239000002994 raw material Substances 0.000 claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
- 239000000284 extract Substances 0.000 claims description 54
- 239000012530 fluid Substances 0.000 claims description 54
- 238000002156 mixing Methods 0.000 claims description 52
- 239000000843 powder Substances 0.000 claims description 50
- 239000008187 granular material Substances 0.000 claims description 30
- 241000218176 Corydalis Species 0.000 claims description 22
- 241000206469 Pulsatilla Species 0.000 claims description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 22
- 235000004347 Perilla Nutrition 0.000 claims description 21
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 21
- 241000220259 Raphanus Species 0.000 claims description 21
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 21
- 241000213006 Angelica dahurica Species 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 238000007873 sieving Methods 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 11
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 241000555712 Forsythia Species 0.000 claims description 6
- 240000003690 Callicarpa japonica Species 0.000 claims description 4
- 235000017595 Callicarpa japonica Nutrition 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 42
- 238000011282 treatment Methods 0.000 abstract description 29
- 208000002193 Pain Diseases 0.000 abstract description 28
- 230000036407 pain Effects 0.000 abstract description 28
- 239000000203 mixture Substances 0.000 abstract description 8
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 230000003213 activating effect Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000012535 impurity Substances 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 22
- 210000002784 stomach Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000922974 Callicarpa bodinieri Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及治疗气滞血瘀型胃痛的药物组合物,可有效解决疗效好,无毒副作用,治疗周期短,无复发的问题,其解决的技术方案是,由以下重量计的原料药制成:延胡索70~80g、白芷35~40g、紫珠叶70~80g、紫苏梗70~80g、连翘35~40g、白头翁35~40g、莱菔子70~80g和碳酸氢钠10~20g,本发明组分配伍科学合理,制备方法简单,易生产,组分间相互支持,辩证治疗,具有理气、活血、止痛的功效,有效用于治疗气滞血瘀型胃痛,且减少对身体的副作用,去除了无效杂质的同时,充分发挥了药物有效成分的作用,是治疗气滞血瘀型胃痛药物上的创新,有显著的经济和社会效益。
Description
技术领域
本发明涉及医药领域,特别是一种治疗气滞血瘀型胃痛的药物组合物。
背景技术
胃痛,中医病证名。多由外感寒邪、饮食所伤、情志不畅和脾胃素虚等病因而引发。胃是主要病变脏腑,常与肝脾等脏有密切关系。胃气郁滞、失于和降是胃痛的主要病机。治疗以理气和胃为大法,根据不同证候,采取相应治法。
气滞血瘀型胃痛症状可见胃痛屡发,痛如针刺刀割,痛有定处而拒按,食后较甚,入夜为重,,或见黑便,时嗳气,舌质紫暗或有瘀点或唇黑,脉沉涩或细涩。《素问举痛论》谓:“百病生于气也,怒则气上,喜则气缓,悲则气消,恐则气下,寒则气收,炅则气泄,惊则气乱,劳则气耗,思则气结”,拈痛即痛之意。说明许多疾病由气而生,气为血帅,血为气母,气滞则血瘀,不痛则痛。
经常胃病者,如果因有其他疾病而需长期服用药物,最好能够向医生请教,看看这些正在服用的药物是否会刺激胃部而致胃不舒服。例如,抗生素、铁剂等,都是会刺激胃励膜的药物。一定要请自己的主治医师,针对自己的服药习惯,给予药物处方的建议。另外,也不要在激烈运动之前或之后马上进餐。因为这样一来,会使得胃部负荷过重,而诱发胃痛。
有人认为偶尔的、少剂量的服用镇痛药不会损害胃肠道,其实不然。研究表明,健康人服用阿司匹林后16分钟即可出现胃粘膜损伤。同样有研究已证实单次或低剂量服用非选择性非甾体类抗炎药,即可引起上消化道出血及穿孔。非甾体抗炎镇痛药对胃肠道的损伤分为两部分,一是药品在胃部停留造成的局部刺激,这点可以通过饭后服用或者使用外用镇痛药进行缓解。但是从根本上镇痛药80%以上的作用都是通过血液循环来影响胃粘膜的,这种伤害是饭后服药和使用外用镇痛药所无法避免的,治疗时间长,而且疗效也不尽人意,易复发。因此,治疗胃痛药物上的改进和创新势在必行。
发明内容
为了克服现有技术缺陷,本发明之目的就是提供一种治疗气滞血瘀型胃痛的药物组合物,可有效解决疗效好,无毒副作用,治疗周期短,无复发的问题。
本发明解决的技术方案是,一种治疗气滞血瘀型胃痛的药物组合物,根据中医理论,针对气滞血瘀型胃痛的发病机理,以理气、活血、止痛为原则,进行辩证配伍,以达到标本兼治的目的。据此,本发明药物组合物是由以下重量计的原料药制成:延胡索70~80g、白芷35~40g、紫珠叶70~80g、紫苏梗70~80g、连翘35~40g、白头翁35~40g、莱菔子70~80g和碳酸氢钠10~20g,其中:
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度60~70%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量8-12倍量的60~70%乙醇,提取2-4小时;第二次加3味原料药材重量6-10倍量的60~70%乙醇,提取1-3小时,过滤,合并两次滤液;减压回收乙醇,浓缩至60℃~80℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量6-10倍的水煎煮两次,每次煎煮1.5~3小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀, 60℃~80℃干燥,粉碎,过80目筛,加淀粉100g-200g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得(成品)。
本发明组分配伍科学合理,制备方法简单,易生产,组分间相互支持,辩证治疗,具有理气、活血、止痛的功效,有效用于治疗气滞血瘀型胃痛,且减少对身体的副作用,去除了无效杂质的同时,充分发挥了药物有效成分的作用,是治疗气滞血瘀型胃痛药物上的创新,有显著的经济和社会效益。
具体实施方式
以下结合实例对本发明的具体实施方式做进一步详细说明。
本发明在具体实施中可由以下实施例给出。
实施例1
本发明一种治疗气滞血瘀型胃痛的药物组合物,由以下重量计的原料药制成:延胡索75g、白芷37.5g、紫珠叶75g、紫苏梗75g、连翘37.5g、白头翁37.5g、莱菔子75g和碳酸氢钠15g,其中:
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度65%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量10倍量的65%乙醇,提取3小时;第二次加3味原料药材重量8倍量的65%乙醇,提取2小时,过滤,合并两次滤液;减压回收乙醇,浓缩至70℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量8倍的水煎煮两次,每次煎煮2小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀,70℃干燥,粉碎,过80目筛,加淀粉150g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得(成品)。
实施例2
本发明一种治疗气滞血瘀型胃痛的药物组合物,由以下重量计的原料药制成:延胡索70g、白芷35g、紫珠叶70g、紫苏梗70g、连翘35g、白头翁35g、莱菔子70g和碳酸氢钠10g,其中:
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度60%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量12倍量的60%乙醇,提取4小时;第二次加3味原料药材重量10倍量的60%乙醇,提取3小时,过滤,合并两次滤液;减压回收乙醇,浓缩至60℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量6倍的水煎煮两次,每次煎煮1.5小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀, 60℃干燥,粉碎,过80目筛,加淀粉100g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得(成品)。
实施例3
本发明一种治疗气滞血瘀型胃痛的药物组合物,由以下重量计的原料药制成:延胡索80g、白芷40g、紫珠叶80g、紫苏梗80g、连翘40g、白头翁40g、莱菔子80g和碳酸氢钠20g,其中:
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度70%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量8倍量的70%乙醇,提取2小时;第二次加3味原料药材重量6倍量的70%乙醇,提取1小时,过滤,合并两次滤液;减压回收乙醇,浓缩至80℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量10倍的水煎煮两次,每次煎煮3小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀, 60℃~80℃干燥,粉碎,过80目筛,加淀粉200g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得(成品)。
实施例4
本发明一种治疗气滞血瘀型胃痛的药物组合物,由以下重量计的原料药制成:延胡索70g、白芷40g、紫珠叶70g、紫苏梗80g、连翘35g、白头翁40g、莱菔子70g和碳酸氢钠20g,其中:
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度75%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量11倍量的75%乙醇,提取2.5小时;第二次加3味原料药材重量9倍量的75%乙醇,提取2.5小时,过滤,合并两次滤液;减压回收乙醇,浓缩至75℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量9倍的水煎煮两次,每次煎煮2.5小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀, 75℃干燥,粉碎,过80目筛,加淀粉130g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得(成品)。
上述药物中,其中:
延胡索:辛、苦,温。归肝、脾经。活血,行气,止痛。用于胸胁、脘腹疼痛,胸痹心痛,经闭痛经,产后瘀阻,跌扑肿痛。具有以下作用:1、镇痛作用; 2、镇静、催眠;3、镇静、催眠;4、抑制胃酸分泌、抗溃疡;5、平滑肌松弛等作用。
白芷:辛,温。归胃、大肠、肺经。解表散寒,祛风止痛,宣通鼻窍,燥湿止带,消肿排脓。用于感冒头痛,眉棱骨痛,鼻塞流涕,鼻鼽,鼻渊,牙痛,带下,疮疡肿痛。具有以下作用:1、抗炎作用; 2、中枢镇痛作用;3、抗病原微生物;4、抗肿瘤;5、保肝作用。
紫珠叶:苦、涩。凉。归肝、肺、胃经。凉血收敛止血,散瘀解毒消肿。用于衄血,咯血,吐血,便血,崩漏,外伤出血,热毒疮疡,水火烫伤。具有以下作用:1、止血作用紫珠水煎剂能缩短实验动物的出血时间及凝血时间,紫珠注射剂无论是静注还是肌注,均有止血作用;2、抗菌作用紫珠水煎液对金黄色葡萄球菌、溶血性链球菌有较强的抑制作用;3、抗炎作用裸花紫珠片稀释液给小鼠灌胃,对冰醋酸所致的小鼠腹部毛细血管通透性增强和二甲苯所致的小鼠耳肿胀有非常显著的抑制作用,并可明显抑制大鼠蛋清性足肿胀形成;4、收敛作用本品含有鞣质,有较强的收敛作用,用于创面,能使蛋白质凝固,干燥结痂,保护肉芽组织,同时有收缩血管、降低毛细血管通透性的作用,故能控制创面液体的外渗,减少体液流失;5、镇痛作用紫珠醇提取物给昆明种小鼠皮下注射,能明显抑制冰醋酸诱发的小鼠扭体反应。
紫苏梗:辛,温。归肺、脾经。理气宽中,止痛,安胎。用于胸膈痞闷,胃脘疼痛,嗳气呕吐,胎动不安。具有以下作用:1、抗菌、抗病毒作用,具有抑制金黄色萄萄球菌和大肠杆菌生长的活性;2、抗炎抗过敏作用,3、调脂保肝的作用;4、抗氧化作用;5、解热作用;6、镇静、镇痛作用。
连翘:苦,微寒。归肺、心、小肠经。清热解毒,消肿散结,疏散风热。用于痈疽,瘰疬,乳痈,丹毒,风热感冒,温病初起,温热入营,高热烦渴,神昏发斑,热淋涩痛。具有以下作用:1、抗氧化作用;2、抗氧化作用;3、非特异性免疫;4、降血脂作用;5、抑制血小板活化因子活性;6、抑制血小板活化因子活性。
白头翁:苦,寒。归胃、大肠经。清热解毒,凉血止痢。用于热毒血痢,阴痒带下。具有以下作用:1. 抗肿瘤作用, 白头翁酸对P-338细胞、Lewis肺癌瘤株及人类巨细胞肺癌瘤株有细胞毒作用;2、增强免疫功能作用,可降低荷瘤小鼠脾指数,升高胸腺指数,另一方面又能加强巨噬细胞活性而提高机体免疫力;3、抗氧化、抗炎,具有阻止肝组织中过氧化物的释放,阻止乙型肝炎病毒的感染;4、杀虫、抑菌,对杀灭溶组织内阿米巴的效果较好,对金黄色葡萄球菌、绿脓杆菌、炭疽杆菌、伤寒杆菌、甲型链球菌、乙型链球菌具有明显的抑制作用。
莱菔子:辛、甘,平。归肺、脾、胃经。消食除胀,降气化痰。用于饮食停滞,脘腹胀痛,大便秘结,积滞泻痢,痰壅喘咳。具有以下作用:有消食除胀,降气化痰、抗病原微生物、解毒、降压、对胃肠运动的作用、治老年便秘、生用探吐痰涎、炒用化痰定喘。
碳酸氢钠: 可迅速中和胃酸,解除胃酸过多或烧心症状,但作用较弱,持续时间较短。
上述各组分配伍科学合理,具有理气、活血、止痛之功效,表里兼治,疗效高,无毒副作用,并经临床试验,取得了非常好的有益技术效果,有关临床资料如下。
一、病例选择
1、病例入选标准:
主症:胃脘胀满,刺痛,痛处拒按,痛有定处,舌质暗红或有瘀点,瘀斑。
次症:黑便,面色暗滞,脉弦涩。
以上主症必具,并具次症1项,即可纳入观察对象,作为入选病例
2、诊断标准
凡具有病例入选标准症状者,并经检查确诊。
二、 治疗方案:
经对128例确诊为气滞血瘀的胃痛并获得知情同意的的患者进行此次疗效观察,随机分为两组,其中治疗组65例,男41例,女24例,年龄30-55岁,对照组共63例,男38例,女25例,年龄30-50岁,两组患者在性别、年龄等方面无明显差别。
对照组:服用市售元胡止痛片,温开水冲服,一次5片,每片0.31g,每日3次,7天为一疗程,1个疗程后统计症候疗效;
治疗组:服用本发明实施例1制备的药物组合物片剂,温开水冲服,本发明制备的药物组合物片剂一次5片,每片0.30g,每日3次,7天为一疗程,1个疗程后统计症候疗效。
三、疗效评定标准
治愈:治疗1个疗程以内,症状、体症消失或基本消失,证候积分减少≥95%;
显效:治疗1个疗程以内,症状、体症明显改善,证候积分减少≥70%;
有效:治疗1个疗程以内,症状、体症均有好转,证候积分减少≥30%;
无效:治疗1个疗程以内症状无明显改善,甚或加重,证候积分减少不足30%。
注:计算公式(尼莫地平法)为:[(治疗前积分-治疗后积分)÷治疗前积分]×100%。
四、统计学处理
经治疗后,疗效结果显示,治疗组患者治愈34例,显效15例,有效11例,总有效率92%;对照组患者治愈24例,显效16例,有效12例,总治愈总有效率82%,两组治疗效果有显著性差异,治疗组治疗效果明显好于对照组(p<0.05),详见表1。
表1:两组患者治疗效果对比(n,%)
组别 | 例数 | 治愈 | 显效 | 有效 | 无效 | 总有效率 |
治疗组 | 65 | 34 | 15 | 11 | 5 | 92.3% |
对照组 | 63 | 24 | 16 | 12 | 11 | 82.5% |
五、典型病例
1、孙某,女,57岁,诊时2年前,西医诊断为慢性萎缩性胃炎,久治未愈。胃脘部经常胀满痛疼,近因生气而愈重。证见胃中灼热疼痛,饥不欲食,大便干燥,脉沉细略数,舌质红少津。服用本发明药物组合物1个疗程后,灼热疼痛症状消失,大便干燥等症状均减,疼痛消失,至今1年无复发。
2、杨某,男,32岁,胃脘胀痛,痛处固定且拒按,疼痛发作时有针刺感觉。不能进食伴有返酸。服用西药治疗后症状状好转,停药一段时间后复发。服用本发明药物组合物1个疗程后,症状消失,痊愈,2年后无复发。
3、张某,男,48岁,出现胃胀、胃痛,大便不畅,嘈杂吐酸,遇气症状加重,舌淡苔白,脉弦。用西药治疗效果不佳。服用本发明药物组合物1个疗程后,症状得到缓解,继续服用1个疗程后,所有症全消失,痊愈,2年后无复发。
六、不良反应
所有观察病例没有发现不良反应,用药前后血、尿、大便常规和心电图等无异常变化,说明临床用药安全性较好。
在对实施例1作试验的同时,还对其他实施例进行了相同的试验,均取得了相同和相近似的结果,这里不再一一列举。
七、结论:
综上所述,服用本发明制备的药物组合物片剂具有理气、活血、止痛作用,该药物组合物控制疗效稳定,复发率低,这可能与该组合物具有较强的理气、活血、止痛作用有关。本发明组方科学合理,组分之间相互支持,辩证治疗,既治表又治里,有效用于治疗气滞血瘀型胃痛,有效率高达92%以上,且无毒副作用,用药安全,疗效稳定可靠,是治疗气滞血瘀型胃痛药物上的一大创新,社会和经济效益显著。
Claims (5)
1.一种治疗气滞血瘀型胃痛的药物组合物,其特征在于,由以下重量计的原料药制成:延胡索70~80g、白芷35~40g、紫珠叶70~80g、紫苏梗70~80g、连翘35~40g、白头翁35~40g、莱菔子70~80g和碳酸氢钠10~20g,其具体制备过程如下 :
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度60~70%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量8-12倍量的60~70%乙醇,提取2-4小时;第二次加3味原料药材重量6-10倍量的60~70%乙醇,提取1-3小时,过滤,合并两次滤液;减压回收乙醇,浓缩至60℃~80℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量6-10倍的水煎煮两次,每次煎煮1.5~3小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀, 60℃~80℃干燥,粉碎,过80目筛,加淀粉100g-200g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得。
2.根据权利要求1所述的治疗气滞血瘀型胃痛的药物组合物,其特征在于,由以下重量计的原料药制成:延胡索75g、白芷37.5g、紫珠叶75g、紫苏梗75g、连翘37.5g、白头翁37.5g、莱菔子75g和碳酸氢钠15g,其具体制备过程如下 :
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度65%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量10倍量的65%乙醇,提取3小时;第二次加3味原料药材重量8倍量的65%乙醇,提取2小时,过滤,合并两次滤液;减压回收乙醇,浓缩至70℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量8倍的水煎煮两次,每次煎煮2小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀,70℃干燥,粉碎,过80目筛,加淀粉150g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得。
3.根据权利要求1所述的治疗气滞血瘀型胃痛的药物组合物,其特征在于,由以下重量计的原料药制成:延胡索70g、白芷35g、紫珠叶70g、紫苏梗70g、连翘35g、白头翁35g、莱菔子70g和碳酸氢钠10g,其具体制备过程如下 :
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度60%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量12倍量的60%乙醇,提取4小时;第二次加3味原料药材重量10倍量的60%乙醇,提取3小时,过滤,合并两次滤液;减压回收乙醇,浓缩至60℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量6倍的水煎煮两次,每次煎煮1.5小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀, 60℃干燥,粉碎,过80目筛,加淀粉100g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得。
4.根据权利要求1所述的治疗气滞血瘀型胃痛的药物组合物,其特征在于,由以下重量计的原料药制成:延胡索80g、白芷40g、紫珠叶80g、紫苏梗80g、连翘40g、白头翁40g、莱菔子80g和碳酸氢钠20g,其具体制备过程如下 :
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度70%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量8倍量的70%乙醇,提取2小时;第二次加3味原料药材重量6倍量的70%乙醇,提取1小时,过滤,合并两次滤液;减压回收乙醇,浓缩至80℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量10倍的水煎煮两次,每次煎煮3小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀, 60℃~80℃干燥,粉碎,过80目筛,加淀粉200g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得。
5.根据权利要求1所述的治疗气滞血瘀型胃痛的药物组合物,其特征在于,由以下重量计的原料药制成:延胡索70g、白芷40g、紫珠叶70g、紫苏梗80g、连翘35g、白头翁40g、莱菔子70g和碳酸氢钠20g,其具体制备过程如下 :
(1)将白芷粉碎成细粉,过100目筛,得白芷细粉;
(2)将延胡索、紫珠叶、莱菔子3味原料药材,混合粉碎成粗粉,用体积浓度75%乙醇浸泡24小时,加热回流提取2次,第一次加3味原料药材重量11倍量的75%乙醇,提取2.5小时;第二次加3味原料药材重量9倍量的75%乙醇,提取2.5小时,过滤,合并两次滤液;减压回收乙醇,浓缩至75℃相对密度1.05~1.10的第一清膏;
(3)将紫苏梗、连翘、白头翁3味原料药材,加3味药材重量9倍的水煎煮两次,每次煎煮2.5小时,合并煎液,趁热滤过,滤液浓缩至60℃测相对密度为1.05~1.10的第二清膏;
(4)合并第一清膏、第二清膏,浓缩至60℃测相对密度为1.20~1.25的第三清膏,第三清膏与白芷细粉混匀, 75℃干燥,粉碎,过80目筛,加淀粉130g,制成颗粒;
(5)在上述颗粒中加入碳酸氢钠,混匀,再加入颗粒重量1%的硬脂酸镁,混匀,压片,包糖衣或薄膜衣,每片重0.30g,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011094000.4A CN112022933B (zh) | 2020-10-14 | 2020-10-14 | 一种治疗气滞血瘀型胃痛的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011094000.4A CN112022933B (zh) | 2020-10-14 | 2020-10-14 | 一种治疗气滞血瘀型胃痛的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112022933A CN112022933A (zh) | 2020-12-04 |
CN112022933B true CN112022933B (zh) | 2021-11-05 |
Family
ID=73573371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011094000.4A Active CN112022933B (zh) | 2020-10-14 | 2020-10-14 | 一种治疗气滞血瘀型胃痛的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112022933B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103877164A (zh) * | 2012-12-21 | 2014-06-25 | 福建建东药业有限公司 | 一种元胡止痛胶囊的制作工艺 |
CN109260269A (zh) * | 2018-11-15 | 2019-01-25 | 张瑞武 | 一种元胡止痛片 |
-
2020
- 2020-10-14 CN CN202011094000.4A patent/CN112022933B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103877164A (zh) * | 2012-12-21 | 2014-06-25 | 福建建东药业有限公司 | 一种元胡止痛胶囊的制作工艺 |
CN109260269A (zh) * | 2018-11-15 | 2019-01-25 | 张瑞武 | 一种元胡止痛片 |
Also Published As
Publication number | Publication date |
---|---|
CN112022933A (zh) | 2020-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205026B (zh) | 一种治疗小儿慢性鼻窦炎的中药组合物及其制备方法 | |
CN103393953A (zh) | 一种促进术后伤口愈合的中药药膏及制备方法 | |
CN104383134A (zh) | 一种治疗静脉抽血伤口感染的中药制剂及其制备方法 | |
CN101966250B (zh) | 治疗灼伤的外敷中药及其制作方法 | |
CN104547698B (zh) | 一种无痛治疗痔疮的中药制剂及其制备方法 | |
CN101439114B (zh) | 一种治疗烧烫伤的中药及其制备方法 | |
CN103611084A (zh) | 一种治疗疮疖药膏及其制备方法 | |
CN103638316B (zh) | 一种治疗皮炎的中药制剂 | |
CN112022933B (zh) | 一种治疗气滞血瘀型胃痛的药物组合物 | |
CN101757053A (zh) | 黄蜀葵花有效部位——总黄酮提取物的制备工艺及新用途 | |
CN103908581A (zh) | 一种治疗膀胱癌的药物及制备方法 | |
CN101653474B (zh) | 用于治疗痔疮的药物及制备方法 | |
CN105232849A (zh) | 一种治疗烧伤的膏药 | |
CN101474329B (zh) | 一种治疗皮肤损伤的麝香愈肤膏 | |
CN105031487A (zh) | 一种治疗湿困脾胃型小儿黄疸的中药组合物 | |
CN107744549A (zh) | 一种治疗牙痛的药物及其制备方法 | |
CN103877390A (zh) | 一种治疗风湿热的中药制剂及制备方法 | |
CN102872210B (zh) | 一种治疗荨麻疹的中药 | |
CN103735847B (zh) | 一种治疗湿疹的药物及制备方法 | |
CN102626491B (zh) | 治疗腰间盘突出外用中草药组合物 | |
CN106822789A (zh) | 一种阑尾炎术后护理中药组合物 | |
CN106620264A (zh) | 一种烧烫伤、跌打伤的中药及制备方法 | |
CN105497267A (zh) | 一种治疗热毒炽盛型小儿黄疸的中药组合物 | |
CN104055979A (zh) | 一种治疗肝胆湿热型慢性胰腺炎的中药制剂 | |
CN104971210A (zh) | 治疗脚癣的外洗剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |